DEA schedule
Is methotrexate a controlled substance?
Federal schedule for methotrexate from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Methotrexate is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and methotrexate is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted methotrexate?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 78 prescription listings from 34 labelers, none with a DEA schedule |
| DEA controlled substances list | methotrexate is not on the list |
Methotrexate NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 81927-204 | JYLAMVO | solution | 2 mg/mL | SHORLA ONCOLOGY INC. | None |
| 61703-124 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 61703-161 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 61703-350 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 61703-350 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 61703-408 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 61703-408 | Methotrexate | injection, solution | 25 mg/mL | Hospira, Inc. | None |
| 54436-010 | Otrexup | injection, solution | 10 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-012 | Otrexup | injection, solution | 12.5 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-015 | Otrexup | injection, solution | 15 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-017 | Otrexup | injection, solution | 17.5 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-020 | Otrexup | injection, solution | 20 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-022 | Otrexup | injection, solution | 22.5 mg/.4mL | Antares Pharma, Inc. | None |
| 54436-025 | Otrexup | injection, solution | 25 mg/.4mL | Antares Pharma, Inc. | None |
| 59137-510 | Rasuvo | injection, solution | 10 mg/.2mL | Medexus Pharma Inc. | None |
| 59137-515 | Rasuvo | injection, solution | 12.5 mg/.25mL | Medexus Pharma Inc. | None |
| 59137-520 | Rasuvo | injection, solution | 15 mg/.3mL | Medexus Pharma Inc. | None |
| 59137-525 | Rasuvo | injection, solution | 17.5 mg/.35mL | Medexus Pharma Inc. | None |
| 59137-530 | Rasuvo | injection, solution | 20 mg/.4mL | Medexus Pharma Inc. | None |
| 59137-535 | Rasuvo | injection, solution | 22.5 mg/.45mL | Medexus Pharma Inc. | None |
| 59137-540 | Rasuvo | injection, solution | 25 mg/.5mL | Medexus Pharma Inc. | None |
| 59137-550 | Rasuvo | injection, solution | 30 mg/.6mL | Medexus Pharma Inc. | None |
| 59137-505 | Rasuvo | injection, solution | 7.5 mg/.15mL | Medexus Pharma Inc. | None |
| 52652-2001 | Xatmep | solution | 2.5 mg/mL | Azurity Pharmaceuticals, Inc. | None |
| 16729-277 | Methotrexate | injection | 25 mg/mL | Accord Healthcare, Inc. | None |
| 0143-9367 | Methotrexate | injection, powder, lyophilized, for solution | 1 g/1 | Hikma Pharmaceuticals USA Inc. | None |
| 0143-9830 | Methotrexate | injection, powder, lyophilized, for solution | 1 g/1 | Hikma Pharmaceuticals USA Inc. | None |
| 63323-122 | Methotrexate | injection, powder, lyophilized, for solution | 1 g/1 | Fresenius Kabi USA, LLC | None |
| 55150-511 | METHOTREXATE | injection, solution | 100 mg/4mL | Eugia US LLC | None |
| 55150-512 | METHOTREXATE | injection, solution | 200 mg/8mL | Eugia US LLC | None |
| 0703-3671 | Methotrexate | injection, solution | 25 mg/mL | Teva Parenteral Medicines, Inc. | None |
| 0703-3675 | Methotrexate | injection, solution | 25 mg/mL | Teva Parenteral Medicines, Inc. | None |
| 0703-3678 | Methotrexate | injection, solution | 25 mg/mL | Teva Parenteral Medicines, Inc. | None |
| 46708-711 | METHOTREXATE | injection, solution | 25 mg/mL | Alembic Pharmaceuticals Limited | None |
| 46708-712 | METHOTREXATE | injection, solution | 25 mg/mL | Alembic Pharmaceuticals Limited | None |
| 62332-711 | METHOTREXATE | injection, solution | 25 mg/mL | Alembic Pharmaceuticals Inc. | None |
| 62332-712 | METHOTREXATE | injection, solution | 25 mg/mL | Alembic Pharmaceuticals Inc. | None |
| 63323-123 | Methotrexate | injection, solution | 25 mg/mL | Fresenius Kabi USA, LLC | None |
| 55150-513 | METHOTREXATE | injection, solution | 250 mg/10mL | Eugia US LLC | None |
| 55150-510 | METHOTREXATE | injection, solution | 50 mg/2mL | Eugia US LLC | None |
Showing 40 of 78 listings.
Questions
Is methotrexate a controlled substance?
No. Methotrexate is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and methotrexate is not on the DEA controlled substances list.
Is methotrexate a narcotic?
No. Methotrexate is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is Folate Analog Metabolic Inhibitor.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.
More on Methotrexate
- What is Methotrexate used for?FDA label uses
- Generic for JylamvoFDA Orange Book
- Generic for XatmepFDA Orange Book
- Generic for RasuvoFDA Orange Book
- What is Rasuvo used for?FDA label uses
- Is Rasuvo a controlled substance?Federal schedule
- Folate Analog Metabolic Inhibitors listFDA drug class
- NDC 52652-2001Methotrexate NDC record
- NDC 54436-010Methotrexate NDC record
- NDC 54436-012Methotrexate NDC record